The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2024 | Implications of MRD progression in patients with NDMM treated with quadruplet therapy & autoSCT
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses the implications of a rise in measurable residual disease (MRD) levels in patients with newly diagnosed multiple myeloma (NDMM) treated with quadruplet therapy and autologous stem cell transplantation (autoSCT). In a cohort of over 200 patients, it was found that a tenfold increase in MRD is a reliable indicator of disease progression, challenging the current paradigm. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
